Department of Otolaryngology-Head and Neck Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Laryngoscope. 2012 Feb;122(2):327-31. doi: 10.1002/lary.22393. Epub 2012 Jan 17.
OBJECTIVES/HYPOTHESIS: Aged vocal folds are characterized by atrophy of the mucosa, which causes mucosal wave deficiency and glottal insufficiency. This clinical trial examined the regenerative effects and safety considerations of basic fibroblast growth factor (bFGF) on restoration of aged vocal folds.
Institutional review board-approved human clinical trial.
Ten patients (6 men and 4 women; mean age, 70.1 years) were recruited in the trial. Ten micrograms of bFGF was injected into each treated vocal fold. Injection was performed unilaterally or bilaterally according to each patient's need and repeated up to seven times if necessary. Patient follow-up continued for at least 6 months. The effectiveness of the treatment was assessed by stroboscopic, acoustic, and aerodynamic measurements.
All patients showed improvement of voice. Significant improvements in maximum phonation time, mean flow rate, jitter, shimmer, and noise-to-harmonic ratio lasted for at least 1 year. No allergic or long-term adverse effects were noted.
This clinical trial suggests that bFGF may be effective and safe as a regenerative agent for aged vocal folds.
目的/假设:老年声带的特征是黏膜萎缩,导致黏膜波缺失和声门不足。本临床试验研究了碱性成纤维细胞生长因子(bFGF)对老年声带恢复的再生作用和安全性考虑。
机构审查委员会批准的人体临床试验。
该试验招募了 10 名患者(6 名男性和 4 名女性;平均年龄 70.1 岁)。每侧声带注射 10 微克 bFGF。根据每位患者的需求,单侧或双侧注射,如果需要,最多重复七次。患者随访至少持续 6 个月。通过频闪喉镜、声学和空气动力学测量评估治疗效果。
所有患者的声音均有改善。最长发声时间、平均流速、抖动、颤抖和噪声-谐波比的显著改善至少持续 1 年。未观察到过敏或长期不良反应。
本临床试验表明,bFGF 作为老年声带的再生剂可能是有效且安全的。